A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients

Taimur Sher, Sikander Ailawadhi, Kena C. Miller, Debbie Manfredi, Margaret Wood, Wei Tan, Gregory Wilding, Myron S. Czuczman, Francisco J. Hernandez-Ilizaliturri, Fredrick Hong, Raman Sood, Saif Soniwala, William Lawrence, Saad Jamshed, Aisha Masood, Daniel Iancu, Kelvin Lee, Asher Chanan-Khan

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

Novel agents have provided a new foundation for multiple myeloma therapies. When combined with other anti-myeloma agents, these compounds significantly enhance clinical efficacy. High-dose steroids are frequently used in anti-myeloma combination regimens; however, the doses employed are often poorly tolerated, especially in patients with concurrent comorbid conditions. We hypothesized that a steroid-independent combination regimen could be developed without significant compromise of efficacy. The availability of such a regimen will be important for patients whose concurrent ailments make them poor candidates for steroid containing anti-myeloma regimens. A phase II single institute, non-randomized clinical trial was conducted to investigate a novel steroid-free three-drug combination of bortezomib (V), pegylated liposomal doxorubicin (D), and thalidomide (T), the VDT regimen. Forty-three newly diagnosed multiple myeloma patients requiring treatment were enrolled on this study. The overall response rate and complete response (CR)+near complete response (nCR) rate was 78% and 35%, respectively. Median time to progression was 29·5months. Fatigue, rash, neuropathy, constipation and infections were the most common side effects. We concluded that VDT is a tolerable and an effective regimen capable of inducing high response rates and can be employed in patients considered to be poor candidates for steroid-based treatment regimens.

Original languageEnglish (US)
Pages (from-to)104-110
Number of pages7
JournalBritish journal of haematology
Volume154
Issue number1
DOIs
StatePublished - Jul 2011

Keywords

  • Clinical trials
  • Multiple myeloma
  • Newly diagnosed multiple myeloma
  • Steroids
  • Thalidomide

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients'. Together they form a unique fingerprint.

  • Cite this

    Sher, T., Ailawadhi, S., Miller, K. C., Manfredi, D., Wood, M., Tan, W., Wilding, G., Czuczman, M. S., Hernandez-Ilizaliturri, F. J., Hong, F., Sood, R., Soniwala, S., Lawrence, W., Jamshed, S., Masood, A., Iancu, D., Lee, K., & Chanan-Khan, A. (2011). A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients. British journal of haematology, 154(1), 104-110. https://doi.org/10.1111/j.1365-2141.2011.08703.x